Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives LAS VEGAS, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, a plant-based research and biopharma technology company, has reported positive results from a study of its potential treatment for cytokine...

Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships LAS VEGAS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Recognizing the glacial pace of traditional drug research and development processes and the adverse effect of this on patients, biopharmaceutical company...

Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety LAS VEGAS, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has initiated new preclinical...

Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation LAS VEGAS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB: GBLX) received positive proof-of-concept data from a human immune cell model supporting their proprietary...

Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference LAS VEGAS, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired biopharmaceutical development company, today announced that their President and Chief Science...